What is new in cancer-associated fibroblast biomarkers?

被引：24
|
作者：
Zhao, Zehua [1 ]
Li, Tianming [1 ]
Yuan, Yuan [2 ,3 ,4 ]
Zhu, Yanmei [1 ]
机构：
[1] Dalian Univ Technol, China Med Univ, Liaoning Canc Hosp & Inst, Dept Pathol,Affiliated Canc Hosp,Canc Hosp, 44 Xiaoheyan Rd, Shenyang 110042, Peoples R China
[2] China Med Univ, Hosp 1, Tumor Etiol & Screening Dept, Canc Inst & Gen Surg, Shenyang, Peoples R China
[3] China Med Univ, Hosp 1, Liaoning Educ Dept, Key Lab Canc Etiol & Prevent, Shenyang, Peoples R China
[4] China Med Univ, Hosp 1, Key Lab GI Canc Etiol & Prevent Liaoning Prov, 155 Nanjing Rd, Shenyang 110001, Peoples R China
来源：
CELL COMMUNICATION AND SIGNALING | 2023年 / 21卷 / 01期
关键词：
Cancer-associated fibroblasts; Biomarker; Heterogeneity; Targeted therapy; CARCINOMA-ASSOCIATED FIBROBLASTS; SMOOTH MUSCLE ACTIN; PODOPLANIN-POSITIVE FIBROBLASTS; ENHANCER-BINDING PROTEIN-1; TO-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; ACTIVATION PROTEIN; TUMOR MICROENVIRONMENT; STROMAL CELLS; TENASCIN-C;
D O I：
10.1186/s12964-023-01125-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The tumor microenvironment is one of the important drivers of tumor development. Cancer-associated fibroblasts (CAFs) are a major component of the tumor stroma and actively participate in tumor development, invasion, metastasis, drug resistance, and other biological behaviors. CAFs are a highly heterogeneous group of cells, a reflection of the diversity of their origin, biomarkers, and functions. The diversity of CAF origin determines the complexity of CAF biomarkers, and CAF subpopulations expressing different biomarkers may play contrasting roles in tumor progression. In this review, we provide an overview of these emerging CAF biomarkers and the biological functions that they suggest, which may give a better understanding of the relationship between CAFs and tumor cells and be of great significance for breakthroughs in precision targeted therapy for tumors.
引用
收藏
页数：23
相关论文
共 50 条
  • [1] What is new in cancer-associated fibroblast biomarkers?
    Zehua Zhao
    Tianming Li
    Yuan Yuan
    Yanmei Zhu
    Cell Communication and Signaling, 21
  • [2] Cancer-associated thrombosis: what is new?
    Mahe, Isabelle
    Benarroch, Samuel
    Djennaoui, Sadji
    Hakem, Rabiaa
    Ghorbel, Abdallah
    Helfer, Helene
    Chidiac, Jean
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (02) : 150 - 157
  • [3] The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment
    Yamamoto, Yurie
    Kasashima, Hiroaki
    Fukui, Yasuhiro
    Tsujio, Gen
    Yashiro, Masakazu
    Maeda, Kiyoshi
    CANCER SCIENCE, 2023, 114 (01) : 16 - 24
  • [4] Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities
    Zhou, Donger
    Zheng, Lei
    CHINESE MEDICAL JOURNAL, 2024, 137 (06) : 638 - 650
  • [5] Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities
    Zhou Donger
    Zheng Lei
    中华医学杂志英文版, 2024, 137 (06)
  • [6] Biomarkers for cancer-associated fibroblasts
    Chencheng Han
    Tongyan Liu
    Rong Yin
    Biomarker Research, 8
  • [7] Biomarkers for cancer-associated fibroblasts
    Han, Chencheng
    Liu, Tongyan
    Yin, Rong
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [8] Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer
    Tokhanbigli, Samaneh
    Haghi, Mehra
    Dua, Kamal
    Oliver, Brian Gregory George
    CANCER DRUG RESISTANCE, 2024, 7
  • [9] Cancer-associated fibroblast heterogeneity in neuroblastoma
    Peterson, Nicolas B.
    Thomas, Paul G.
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Cancer-associated fibroblast heterogeneity in chordoma
    Henry, Jack C.
    Cameron, Angus J. M.
    JOURNAL OF PATHOLOGY, 2025,
12345